Natera is a diagnostics company specializing in cell-free DNA testing for reproductive health, oncology and organ transplant care. Flagship offerings include non-invasive prenatal screening, molecular residual disease tests such as Signatera, and transplant rejection monitoring. Hospitals, clinics and specialists use its assays to guide risk assessment, treatment decisions and long-term patient monitoring.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 546.6 | — | -100.9 | — |
| Q3 2025 | 592.2 | — | -87.5 | — |
| Q4 2025 | 665.5 | — | 47.3 | — |
| Q1 2026 | 696.6 | — | -85.1 | — |
| Q2 2026 | 752.8 | 37.7% | -67 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Baker Hughes Company (BKR), eBay Inc. (EBAY), Honeywell Aerospace Inc. (HONA), Atlassian Corporation (TEAM), Nasdaq, Inc. (NDAQ), argenx SE (ARGX)